Latest content
- Galderma’s Nemluvio shows sustained improvements in moderate-to-severe atopic dermatitis
- Inizio Evoke appoints Barbara Patchefsky as Global Client Lead
- MSD announces phase 2 results for tulisokibart in moderate to severe hidradenitis suppurativa
- Inizio Evoke appoints Brian Gundich as EVP, AI Enablement
- Roche’s fenebrutinib receives FDA filing acceptance for relapsing and primary progressive MS
Latest intelligence
- Strengthening engagement with HCPs needs deep understanding not digital bombardment
- Cell and gene therapies – moving from niche innovations towards broader clinical use
- Creating a strong patent portfolio through constant communication
- Leading through complexity
- The Amazon reckoning: GLP-1s and the consumer lifestyle shift – why the molecule is no longer enough